Humana Inc.
Humana Inc. HUM Peers
See (HUM) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HUM | $230.48 | +1.46% | 27.8B | 16.27 | $14.17 | +1.53% |
| UNH | $303.14 | +2.47% | 275B | 12.69 | $23.89 | +2.77% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.69% |
| ELV | $393.38 | +2.27% | 88.9B | 15.31 | $25.69 | +1.69% |
| CI | $312.17 | +0.37% | 83.4B | 17.39 | $17.95 | +1.86% |
| CVS | $63.58 | +0.79% | 80.4B | 15.17 | $4.19 | +4.19% |
| CNC | $55.14 | +0.55% | 27.4B | 8.13 | $6.78 | N/A |
| MOH | $296.80 | +1.10% | 16.1B | 14.34 | $20.70 | N/A |
| OSCR | $15.43 | -1.44% | 3.4B | 38.56 | $0.40 | N/A |
| ALHC | $15.22 | +2.91% | 3B | -32.38 | -$0.47 | N/A |
Stock Comparison
HUM vs UNH Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, UNH has a market cap of 275B. Regarding current trading prices, HUM is priced at $230.48, while UNH trades at $303.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas UNH's P/E ratio is 12.69. In terms of profitability, HUM's ROE is +0.10%, compared to UNH's ROE of +0.24%. Regarding short-term risk, HUM is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs ANTM Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, HUM is priced at $230.48, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas ANTM's P/E ratio is 18.99. In terms of profitability, HUM's ROE is +0.10%, compared to ANTM's ROE of +0.14%. Regarding short-term risk, HUM is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs ELV Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, ELV has a market cap of 88.9B. Regarding current trading prices, HUM is priced at $230.48, while ELV trades at $393.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas ELV's P/E ratio is 15.31. In terms of profitability, HUM's ROE is +0.10%, compared to ELV's ROE of +0.14%. Regarding short-term risk, HUM is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs CI Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, CI has a market cap of 83.4B. Regarding current trading prices, HUM is priced at $230.48, while CI trades at $312.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas CI's P/E ratio is 17.39. In terms of profitability, HUM's ROE is +0.10%, compared to CI's ROE of +0.12%. Regarding short-term risk, HUM is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs CVS Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, CVS has a market cap of 80.4B. Regarding current trading prices, HUM is priced at $230.48, while CVS trades at $63.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas CVS's P/E ratio is 15.17. In terms of profitability, HUM's ROE is +0.10%, compared to CVS's ROE of +0.07%. Regarding short-term risk, HUM is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs CNC Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, CNC has a market cap of 27.4B. Regarding current trading prices, HUM is priced at $230.48, while CNC trades at $55.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas CNC's P/E ratio is 8.13. In terms of profitability, HUM's ROE is +0.10%, compared to CNC's ROE of +0.13%. Regarding short-term risk, HUM is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs MOH Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, MOH has a market cap of 16.1B. Regarding current trading prices, HUM is priced at $230.48, while MOH trades at $296.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas MOH's P/E ratio is 14.34. In terms of profitability, HUM's ROE is +0.10%, compared to MOH's ROE of +0.26%. Regarding short-term risk, HUM is more volatile compared to MOH. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs OSCR Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, OSCR has a market cap of 3.4B. Regarding current trading prices, HUM is priced at $230.48, while OSCR trades at $15.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas OSCR's P/E ratio is 38.56. In terms of profitability, HUM's ROE is +0.10%, compared to OSCR's ROE of +0.11%. Regarding short-term risk, HUM is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs ALHC Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, ALHC has a market cap of 3B. Regarding current trading prices, HUM is priced at $230.48, while ALHC trades at $15.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas ALHC's P/E ratio is -32.38. In terms of profitability, HUM's ROE is +0.10%, compared to ALHC's ROE of -0.81%. Regarding short-term risk, HUM is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs CLOV Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, CLOV has a market cap of 1.6B. Regarding current trading prices, HUM is priced at $230.48, while CLOV trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas CLOV's P/E ratio is -76.37. In terms of profitability, HUM's ROE is +0.10%, compared to CLOV's ROE of -0.07%. Regarding short-term risk, HUM is more volatile compared to CLOV. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs BHG Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, HUM is priced at $230.48, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas BHG's P/E ratio is -0.12. In terms of profitability, HUM's ROE is +0.10%, compared to BHG's ROE of -0.47%. Regarding short-term risk, HUM is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs BMGL Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, BMGL has a market cap of 91.8M. Regarding current trading prices, HUM is priced at $230.48, while BMGL trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas BMGL's P/E ratio is 43.67. In terms of profitability, HUM's ROE is +0.10%, compared to BMGL's ROE of +0.32%. Regarding short-term risk, HUM is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs MRAI Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, MRAI has a market cap of 20M. Regarding current trading prices, HUM is priced at $230.48, while MRAI trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas MRAI's P/E ratio is -0.46. In terms of profitability, HUM's ROE is +0.10%, compared to MRAI's ROE of +0.75%. Regarding short-term risk, HUM is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs IVF Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, IVF has a market cap of 3.1M. Regarding current trading prices, HUM is priced at $230.48, while IVF trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas IVF's P/E ratio is -0.04. In terms of profitability, HUM's ROE is +0.10%, compared to IVF's ROE of -2.58%. Regarding short-term risk, HUM is less volatile compared to IVF. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs NIVF Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, NIVF has a market cap of 1.6M. Regarding current trading prices, HUM is priced at $230.48, while NIVF trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas NIVF's P/E ratio is -0.01. In terms of profitability, HUM's ROE is +0.10%, compared to NIVF's ROE of +0.03%. Regarding short-term risk, HUM is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs GTS Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, GTS has a market cap of 0. Regarding current trading prices, HUM is priced at $230.48, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas GTS's P/E ratio is 10.41. In terms of profitability, HUM's ROE is +0.10%, compared to GTS's ROE of +0.07%. Regarding short-term risk, HUM is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs MGLN Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.8B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, HUM is priced at $230.48, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.27, whereas MGLN's P/E ratio is 8.49. In terms of profitability, HUM's ROE is +0.10%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, HUM is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.